Share this article and save a life!
AI just proved it can catch breast cancer we’re missing.
A groundbreaking Swedish trial of 100,000 women just delivered the evidence we’ve been waiting for.
AI-supported mammography isn’t just hype anymore. The numbers from The Lancet study are striking:
📊 The AI advantage:
• 81% of cancers caught during screening (vs 74% standard)
• 12% fewer interval cancers between screenings
• 44% reduction in radiologist workload
But here’s what matters most:
The AI group found 16% fewer invasive cancers, 21% fewer large tumors, and 27% fewer aggressive cancers.
Think about that. We’re not just finding more cancers, we’re catching them when they’re smaller, less aggressive, and more treatable.
💡 The workforce impact is equally compelling.
With radiologist burnout at crisis levels and screening demand growing, AI acts as a co-pilot, not a replacement. One radiologist plus AI can now do the work that previously required two specialists.
This means shorter wait times for patients and more time for radiologists to focus on complex cases.
The U.S. is taking notice. The PRISM trial just launched with $16 million in funding, testing AI across California, Florida, Massachusetts, Washington, and Wisconsin.
Here’s my take:
We’re witnessing a fundamental shift in cancer screening. AI isn’t replacing clinical judgment, it’s amplifying it. When a technology can simultaneously improve outcomes AND reduce workforce strain, that’s not innovation, that’s transformation.
The question isn’t whether AI belongs in mammography anymore.
It’s how quickly we can scale this to save more lives.
♻️ Repost if earlier cancer detection should be our top priority
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
